Location History:
- Berriozar, ES (2006 - 2009)
- Pamplona-Navarra, ES (2012)
- Pamplona, ES (2010 - 2023)
Company Filing History:
Years Active: 2006-2023
Title: Innovations of Juan José Lasarte Sagastibelza
Introduction
Juan José Lasarte Sagastibelza is a prominent inventor based in Pamplona, Spain. He has made significant contributions to the field of biomedical research, particularly in the development of peptides that have potential applications in cancer treatment. With a total of seven patents to his name, his work is recognized for its innovative approach to addressing complex medical challenges.
Latest Patents
One of his latest patents is focused on FOXP3-binding peptides and their uses. The invention provides peptides of a specific general formula, which includes various components that enhance their binding efficiency to FoxP3. These peptides are designed to inhibit and block Treg cell functionality, making them valuable in cancer therapies. The patent also includes constructs that comprise the peptide, as well as combinations that enhance its effectiveness in medical applications.
Career Highlights
Throughout his career, Juan José has worked with notable organizations such as Proyecto De Biomedicina Cima, S.L. and Fundación Para La Investigación Médica Aplicada. His experience in these institutions has allowed him to collaborate on groundbreaking research and contribute to advancements in medical science.
Collaborations
He has collaborated with esteemed colleagues, including Inés Noelia Casares Lagar and Jesús Maria Prieto Valtueña. These partnerships have fostered a collaborative environment that promotes innovation and the sharing of ideas in the field of biomedical research.
Conclusion
Juan José Lasarte Sagastibelza's contributions to the field of biomedical innovation are noteworthy. His work on FOXP3-binding peptides exemplifies his commitment to advancing cancer treatment. His collaborations and career achievements further highlight his role as a leading inventor in the medical research community.